Cogent Biosciences Inc
$ 36.63
2.35%
01 May - close price
- Market Cap 6,112,968,000 USD
- Current Price $ 36.63
- High / Low $ 37.01 / 35.42
- Stock P/E N/A
- Book Value 3.40
- EPS -2.16
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.33 %
- ROE -0.74 %
- 52 Week High 43.73
- 52 Week Low 4.55
About
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$54.17
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-17 | 2025-11-03 | 2025-08-05 | 2025-05-05 | 2025-02-24 | 2024-10-31 | 2024-08-06 | 2024-05-07 | 2024-02-26 | 2023-11-02 | 2023-08-08 | 2023-05-09 |
| Reported EPS | -0.5628 | -0.5 | -1.27 | -0.5249 | -0.09 | -0.6412 | -0.59 | -0.62 | -0.63 | -0.64 | -0.59 | -0.54 |
| Estimated EPS | -0.5101 | -0.5217 | -0.5867 | -0.5771 | -0.5837 | -0.5664 | -0.56 | -0.52 | -0.56 | -0.5 | -0.54 | -0.57 |
| Surprise | -0.0527 | 0.0217 | -0.6833 | 0.0522 | 0.4937 | -0.0748 | -0.03 | -0.1 | -0.07 | -0.14 | -0.05 | 0.03 |
| Surprise Percentage | -10.3313% | 4.1595% | -116.465% | 9.0452% | 84.5811% | -13.2062% | -5.3571% | -19.2308% | -12.5% | -28% | -9.2593% | 5.2632% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.53 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: COGT
2026-04-29 10:39:28
The Teachers Retirement System of the State of Kentucky initiated a new position in Cogent Biosciences (NASDAQ:COGT), acquiring 37,445 shares valued at approximately $1.33 million in Q4. This move is part of broader institutional interest, with other major investors like Fairmount Funds and Vanguard also increasing their stakes. Despite a recent earnings miss, analysts generally hold a bullish outlook for Cogent Biosciences, setting an average price target of $43.45.
2026-04-28 18:50:39
Cogent Biosciences (NASDAQ:COGT) experienced a significant 30.9% drop in short interest in April, totaling 12,038,491 shares. The company maintains a "Moderate Buy" consensus rating from analysts with an average price target of $43.45. Trading near $36.56, Cogent Biosciences has a market capitalization of $6.24 billion and recently reported a quarterly loss of ($0.55) EPS.
2026-04-28 15:09:39
Cogent Biosciences (COGT) is projected to report its Q1 2026 earnings before the market opens on Tuesday, May 5th, with analysts forecasting a loss of ($0.53) per share. The company, a clinical-stage biopharmaceutical firm, will hold its earnings call on May 6th, and has an average "Moderate Buy" rating from analysts with an average price target of $43.45. Its stock price recently saw a slight increase, trading at $36.79, and shows significant institutional interest with several firms newly acquiring stakes.
2026-04-27 07:10:24
Cogent Biosciences (COGT) shares rose after the FDA accepted its New Drug Application (NDA) for bezuclastinib to treat non-advanced systemic mastocytosis (SM). The FDA granted Priority Review, setting a PDUFA date for February 28, 2027. This acceptance marks a significant step for Cogent in bringing a new treatment option to patients with this rare disease.
2026-04-27 05:39:56
Cogent Biosciences (COGT) presented new preclinical data for its KRAS and ErbB2 candidates at AACR 2026, showcasing positive selectivity, activity, and safety. The stock is trading at $36.81, below the average analyst target of $54.17. The article explores whether the company's Price-to-Book ratio of 10.8x is justified, noting it appears expensive compared to broad biotech peers but discounted within its closer peer group, while also highlighting risks such as trial disappointments and funding needs.
2026-04-26 19:39:28
Cogent Biosciences (COGT) is under scrutiny following new preclinical data for its KRAS and ErbB2 drug candidates presented at AACR 2026. The company's stock, currently at $36.81, trades at a significant discount to the average analyst target of $54.17. While its price-to-book ratio of 10.8x appears high compared to the wider biotech industry, it is a considerable discount when set against closer peers, indicating a potentially mispriced oncology story that necessitates further investor review.
